As you may know, the 2018 congress of the European Association of Urology (EAU) has just been held in Copenhagen, Denmark.
At this congress the new EAU Guidelines were presented.
We are pleased to announce that SelectMDx has been included in the 2018 EAU guidelines:
“To avoid unnecessary biopsies, offer further risk-assessment to asymptomatic men with a normal DRE and a PSA level between 2-10 ng/ml prior to performing a biopsy. Use one of the following tools:
- Risk calculator
- Additional serum or urine-based test (e.g. prostate health index test, four kallikrein score, prostate cancer gene 3, HOXC6/DLX1(SelectMDx)),
- Or imaging
The SelectMDx test is based on mRNA biomarker isolation from urine. The presence of HOXC6 and DLX1 mRNA levels is assessed to provide an estimate of the risk of both presence of PCa on biopsy as well as presence of high-risk cancer.
The guidelines committee states that ‘Based of the available evidence, some biomarkers could help in discriminating between aggressive and non-aggressive tumours with an additional value compared to the prognostic parameters currently used by clinicians”.
